As IBM prepares to report first-quarter 2026 results on April 22, the technology giant finds itself at a strategic crossroads. Its shares have tumbled more than 18% since the start of the year, trading at 202.85 euros, a level significantly below the 200-day moving average. This market performance starkly contrasts with a backdrop of rising analyst estimates and major corporate actions, setting the stage for a pivotal earnings call.
The recent completion of the Confluent acquisition for $31.00 per share in cash, finalized on March 17, represents a cornerstone of IBM’s strategy. The $11 billion deal aims to create a unified data architecture for AI agents by integrating Confluent with existing platforms like watsonx.data, IBM MQ, and IBM Z. The company’s rationale is clear: autonomous AI systems require real-time data streams. By controlling this infrastructure, IBM positions itself at a critical leverage point in the enterprise AI market. Management expects the acquisition to contribute positively to EBITDA in its first full year and to boost free cash flow in the second.
Simultaneously, IBM is executing a profound overhaul of its hardware infrastructure for the AI era. A surprise strategic partnership with chip designer Arm is at the heart of this shift. The initiative focuses on developing dual-architecture hardware to integrate Arm-based software environments directly into core enterprise platforms like IBM Z and LinuxONE through virtualization. This move opens IBM’s business-critical systems to a multi-architecture landscape beyond traditional x86 and Power processors.
This hardware push is supported by continued investment in proprietary technology, including the Telum II processor and the Spyre accelerator. Combined with a recently deepened cooperation with Nvidia, IBM is building a comprehensive ecosystem designed to move compute-intensive AI applications from experimentation into daily productive use.
Should investors sell immediately? Or is it worth buying IBM?
Financially, the focus on AI is already making an impact. The company’s AI-related bookings surged to $12.5 billion by the end of 2025, a substantial increase from the $5 billion recorded at the start of that year. For the full year 2025, IBM generated $67.5 billion in revenue and $14.7 billion in free cash flow, achieving 8% growth. The company has reaffirmed its target of over 5% revenue growth for 2026.
Despite the operational momentum, the stock’s weakness reflects broader tech sector selling and concerns over competitive pressure from new AI providers. The shares currently trade below their 200-day average of $277.20 and well off their 52-week high of $324.90. However, analyst sentiment tells a different story. Earnings per share estimates for 2026 have been raised by 6.6% over the past year to $12.44, while forecasts for 2027 have increased by 5.4% to $13.36. IBM has a strong track record of exceeding expectations, beating consensus estimates by an average of 7.9% over the past four quarters.
One area of minimal concern, according to CFO James Kavanaugh, is the impact of global tariffs. Goods imported into the United States account for less than five percent of total spending, providing a significant buffer against trade conflicts. The company is also evaluating alternative supply sources for any affected components.
The upcoming earnings report will serve as the first major test for IBM’s dual-track strategy. Investors will be listening closely for management’s commentary on the early integration of Confluent, the progress of new hardware alliances, and the translation of its robust AI order book into improved margins. The central question remains whether the recent share price decline is fundamentally justified or presents a disconnect from the company’s strategic positioning and financial trajectory.
Ad
IBM Stock: Buy or Sell?! New IBM Analysis from April 10 delivers the answer:
The latest IBM figures speak for themselves: Urgent action needed for IBM investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 10.
IBM: Buy or sell? Read more here...
